Last updated: February 19, 2026
Lexiscan (regadenoson) is a vasodilator used in myocardial perfusion imaging to diagnose coronary artery disease. It is marketed primarily by Sanofi. The drug was approved by the U.S. Food and Drug Administration (FDA) in 2011.
Major Suppliers of Lexiscan
Originator and Primary Supplier
- Sanofi
- Holds the original marketing authorization for Lexiscan (regadenoson).
- Manufactures and supplies the drug primarily to North America, Europe, and other markets.
- FDA NDA approval: January 2011 [1].
Authorized Distributors and Importers
- Sanofi’s global distribution network supplies Lexiscan through authorized distributors, which may vary by country.
- Distribution channels include pharmacy chains, hospitals, and specialty pharmacies in regions where Lexiscan is approved.
Contract Manufacturers and Supply Chain Considerations
- Specific contract manufacturers for Lexiscan are not publicly disclosed due to confidentiality.
- Sanofi's manufacturing facilities for regadenoson are located primarily in Europe and North America.
Patent and Market Exclusivity
- Patent protection for Lexiscan was granted in multiple jurisdictions.
- Market exclusivity generally lasted until late 2020, with some patent rights expiring earlier or later depending on jurisdiction.
Generic and Biosimilar Status
- As of 2023, no approved generic versions of Lexiscan are available in the United States or Europe.
- Clinical development of biosimilars or generics in other regions is ongoing; however, regulatory approval has not been granted.
Potential Future Suppliers
- Market entry of generics depends on patent expiry and regulatory approval processes.
- Several pharmaceutical companies are researching adenosine receptor agonists similar to regadenoson, but none have secured regulatory approval as generic Lexiscan.
Regional Regulatory Approvals
| Region |
Approval Status |
Key Notes |
| United States |
Approved (FDA) |
Marketed by Sanofi |
| Europe |
Approved (EMA) |
Marketed under same or similar branding |
| Japan |
Approved |
Registration pending, local manufacturing likely |
| Australia, Canada |
Approved |
via local regulatory bodies |
Supply Risks and Key Considerations
- Manufacturing concentration at Sanofi increases supply chain risk if Sanofi faces production issues.
- Regulatory restrictions and patent status influence market entry for competitors.
- Current lack of generic options limits market competition; prices remain higher than typical generic drugs.
Summary
Sanofi is the primary and most prominent supplier of Lexiscan globally. No significant generic or biosimilar competitors exist as of 2023. Supply depends predominantly on Sanofi’s manufacturing capacity and distribution channels. Market access varies based on regional regulatory approvals and patent status.
Key Takeaways
- Sanofi is the sole supplier of Lexiscan with exclusive rights in most markets.
- Patent protection ended in several jurisdictions but no generics are available yet.
- Supply chain concentration with limited manufacturing sources presents potential risks.
- Regional approvals are complete in the U.S., Europe, and select markets; others are pending.
- The future landscape depends on patent expirations, regulatory approvals, and development of biosimilars.
FAQs
1. Who manufactures Lexiscan?
Sanofi is the manufacturer and primary supplier of Lexiscan globally.
2. Are there any generic versions of Lexiscan?
No. As of 2023, there are no FDA-approved generics or biosimilars of Lexiscan.
3. How does patent expiry affect Lexiscan supply?
Patent expirations open the potential for generic development, but regulatory approval for generics has not yet occurred.
4. What regions have approved Lexiscan?
The United States, Europe, Japan, Australia, and Canada have approved Lexiscan.
5. What are the main supply risks for Lexiscan?
Supply risks include manufacturing concentration at Sanofi, regulatory restrictions, and patent protections limiting generic entry.
References
[1] U.S. Food and Drug Administration. (2011). FDA approves Lexiscan for cardiac imaging. Retrieved from https://www.fda.gov/
